Search

Your search keyword '"Jeon, Hyun Jung"' showing total 23 results
Start Over Author "Jeon, Hyun Jung"
23 results on '"Jeon, Hyun Jung"'

13. 142

Author

Park, Hye-Lim, primary, Min, Jun-Ki, additional, Lee, Sang-Myeong, additional, Cho, Mi-La, additional, Moon, Su-Jin, additional, Kim, Inki, additional, Lee, Dong-Hee, additional, Park, Sooho, additional, Jeon, Hyun-Jung, additional, Lee, Sang-Yeon, additional, Choi, Seul-Gi, additional, and Nam, Jae-Hwan, additional

Published
2014
Full Text
View/download PDF

19. Mouse Orthotopic Lung Cancer Model Induced by PC14PE6

Author

Cui, Zheng Yun, primary, Ahn, Jin Seok, additional, Lee, Jee Yun, additional, Kim, Won Seog, additional, Lim, Ho Yeong, additional, Jeon, Hyun Jung, additional, Suh, Soo Won, additional, Kim, Jin Hoon, additional, Kong, Won Ho, additional, Kang, Ji Min, additional, Nam, Do Hyun, additional, and Park, Keunchil, additional

Published
2006
Full Text
View/download PDF

22. High Incidence of Tacrolimus-Associated Posttransplantation Diabetes in the Korean Renal Allograft Recipients According to American Diabetes Association Criteria.

Author

Min Cho, Young, Park, Kyong Soo, Jung, Hye Seung, Jeon, Hyun Jung, Ahn, Curie, Ha, Jongwon, Kim, Sang Joon, Rhee, Byoung Doo, Kim, Seong Yeon, and Lee, Hong Kyu

Subjects
DIABETES, TACROLIMUS, IMMUNOSUPPRESSION
Abstract

OBJECTIVE — The incidence of posttransplantation diabetes mellitus (PTDM) has been reported to vary according to different study populations or different definitions. In this study, using American Diabetes Association criteria, the incidence and clinical characteristics of PTDM in Korean renal allograft recipients undergoing tacrolimus-based immunosuppression were examined. RESEARCH DESIGN AND METHODS — A total of 21 patients taking tacrolimus as primary immunosuppressant were recruited and tested with a serial 75-g oral glucose tolerance test at 0, 1, 3, and 6 months after renal transplantation. RESULTS — The cumulative incidence of PTDM was 52.4% at 1 month and 57.1% at 3 and 6 months. The baseline characteristics of the PTDM group were old age (especially >40 years), a high BMI, a high fasting glucose level, a high plasma insulin level, and increased insulin resistance. Among these parameters, old age was the only independent risk factor. The insulin secretory capacity in the PTDM group was maximally suppressed 3 months after transplantation. Thereafter, it was gradually restored along with dose reduction of tacrolimus. CONCLUSIONS — Routine screening for PTDM is necessary in patients over 40 years of age who are undergoing a relatively higher dose tacrolimus therapy during the early course of postrenal transplantation. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

23. Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.

Author

Son MJ, Kim JS, Kim MH, Song HS, Kim JT, Kim H, Shin T, Jeon HJ, Lee DS, Park SY, Kim YJ, Kim JH, and Nam DH

Subjects
Animals, Apoptosis drug effects, Cell Proliferation, Dacarbazine pharmacology, Gene Expression Profiling, Humans, In Situ Nick-End Labeling, Rats, Rats, Sprague-Dawley, Temozolomide, Transplantation, Heterologous, Angiogenesis Inhibitors pharmacology, Antineoplastic Agents, Alkylating pharmacology, Brain Neoplasms drug therapy, Dacarbazine analogs & derivatives, Glioma drug therapy, Neovascularization, Pathologic, Thalidomide pharmacology
Abstract

The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma. Combination treatment with TMZ and THD in patients with glioblastoma multiforme (GBM) appears to be more effective than treatment with either drug alone. To investigate the mechanism of this anti-tumor effect, we examined the combined effects of TMZ and THD in a rat glioma xenograft model. We found that combination treatment markedly inhibited the growth of tumors that were orthotopically implanted into rat brains. Using proliferating cell nuclear antigen (PCNA) staining, we observed a significant decrease in cell proliferation in these tumors. CD31 staining of the microvasculature revealed a significant decrease in angiogenesis. We also found increased apoptosis in treated tumors by terminal deoxynucleotidyl-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay. We further demonstrated that the expression of angiogenic factors, such as vascular endothelial cell growth factor (VEGF) and basic fibroblastic growth factor (bFGF), were inhibited by THD. THD also decreased the number of ED1-positive, activated macrophages or microglial cells, which produce pro-angiogenic molecules around the glioma. Taken together, these results suggest that combination treatment with TMZ and THD inhibits tumor growth via the induction of apoptosis and the inhibition of angiogenesis in a rat model and may be a promising therapy for malignant gliomas.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results